» Articles » PMID: 19148805

Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma in Japan: the J-HCC Guidelines

Overview
Journal J Gastroenterol
Specialty Gastroenterology
Date 2009 Jan 17
PMID 19148805
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

The "Clinical Practice Guidelines for Hepatocellular Carcinoma (HCC)," the first evidence-based guidelines for the treatment of HCC in Japan, were compiled by an expert panel supported by the Japanese Ministry of Health, Labour, and Welfare. The English translation has been completed (http://www.jsh.or.jp), and its summary has just been published (Hepatol Res 38:37-51, 2008). This set of guidelines covers six research fields: prevention, diagnosis and surveillance, surgery, chemotherapy, transarterial chemoembolization, and percutaneous local ablation therapy. For the users' convenience, practical algorithms for the surveillance and treatment of HCC were also created, which are based on evidence from articles selected for the guidelines and modified according to the current status of medical practice in Japan. One year after their publication, the J-HCC Guidelines have become well disseminated among both specialists and primary care physicians in Japan. As expected, these guidelines have begun to be applied at every level of clinical decision making for HCC. The first revision of the J-HCC Guidelines is now in process, and it is scheduled to be completed by March 2009.

Citing Articles

Application and progress of the detection technologies in hepatocellular carcinoma.

Yan Q, Sun Y, An R, Liu F, Fang Q, Wang Z Genes Dis. 2023; 10(5):1857-1869.

PMID: 37492708 PMC: 10363596. DOI: 10.1016/j.gendis.2022.04.003.


2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.

J Liver Cancer. 2023; 23(1):1-120.

PMID: 37384024 PMC: 10202234. DOI: 10.17998/jlc.2022.11.07.


2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Korean J Radiol. 2022; 23(12):1126-1240.

PMID: 36447411 PMC: 9747269. DOI: 10.3348/kjr.2022.0822.


2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.

Clin Mol Hepatol. 2022; 28(4):583-705.

PMID: 36263666 PMC: 9597235. DOI: 10.3350/cmh.2022.0294.


Determination of hepatic extraction fraction with gadoxetate low-temporal resolution DCE-MRI-based deconvolution analysis: validation with ALBI score and Child-Pugh class.

Phonlakrai M, Ramadan S, Simpson J, Gholizadeh N, Arm J, Skehan K J Med Radiat Sci. 2022; 70 Suppl 2:48-58.

PMID: 36088635 PMC: 10122932. DOI: 10.1002/jmrs.617.


References
1.
Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S . Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res. 2007; 38(1):37-51. DOI: 10.1111/j.1872-034X.2007.00216.x. View

2.
Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F . Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334(11):693-9. DOI: 10.1056/NEJM199603143341104. View

3.
Poon R, Fan S, Wong J . Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg. 2002; 235(4):466-86. PMC: 1422461. DOI: 10.1097/00000658-200204000-00004. View

4.
Bruix J, Sherman M, Llovet J, Beaugrand M, Lencioni R, Burroughs A . Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001; 35(3):421-30. DOI: 10.1016/s0168-8278(01)00130-1. View

5.
Ishizawa T, Hasegawa K, Aoki T, Takahashi M, Inoue Y, Sano K . Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008; 134(7):1908-16. DOI: 10.1053/j.gastro.2008.02.091. View